An atrial fibrillation device maker has 70% upside, JMP Securities says
Analyst Daniel Stauder initiated coverage of the stock with an outperform rating and $60 price target, implying shares could soar by almost 70%.
Stay updated with breaking news from Open Ablation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Analyst Daniel Stauder initiated coverage of the stock with an outperform rating and $60 price target, implying shares could soar by almost 70%.
AtriCure Inc (ATRC) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. AtriCure Inc (NASDAQ: ATRC) Operator Good afternoon and welcome to AtriCure's First Quarter 2021 Earnings Conference Call. My name is Snell, and I'll be your coordinator for the call today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Lyn...